Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:02:29.727Z.
Calculation as of: 2026-10-06T15:02:29.727Z.
Quote observation: 2026-10-06T15:00:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a99f3f088f54f9f9c0225e5104dac3e52b54f392bb47ad8d1f9af79329b73e7d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Edgewise Therapeutics, Inc.
Market Cap
$4.35B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.37B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.40B
Price/OCF Ratio
N/A
TTM Avg
17.89
3Y Avg
33.70
5Y Avg
30.73
Market Cap
$4.42B
Price/OCF Ratio
N/A
TTM Avg
17.21
3Y Avg
17.21
5Y Avg
17.21
Market Cap
$4.69B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.65B
Price/OCF Ratio
13.40
TTM Avg
16.00
3Y Avg
16.81
5Y Avg
18.87
Market Cap
$4.65B
Price/OCF Ratio
21.35
TTM Avg
18.81
3Y Avg
169.88
5Y Avg
191.97
Market Cap
$4.03B
Price/OCF Ratio
N/A
TTM Avg
94.85
3Y Avg
72.28
5Y Avg
103.02
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc. (EWTX) | $4.35B | N/A | N/A | N/A | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.37B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.40B | N/A | 17.89 | 33.70 | 30.73 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.42B | N/A | 17.21 | 17.21 | 17.21 |
| LivaNova PLC (LIVN)vs › | $4.14B | 16.62 | 15.36 | 25.92 | 31.19 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.69B | N/A | N/A | N/A | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 13.40 | 16.00 | 16.81 | 18.87 |
| LifeStance Health Group, Inc. (LFST)vs › | $4.65B | 21.35 | 18.81 | 169.88 | 191.97 |
| AbCellera Biologics Inc. (ABCL)vs › | $4.03B | N/A | 94.85 | 72.28 | 103.02 |
| BillionToOne, Inc. (BLLN)vs › | $4.67B | 102.90 | 302.47 | 302.47 | 302.47 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
